U.S. Consumer Durables Stock News

Q4 earnings turn profitable as full year stays in the red Quanex Building Products (NX) just posted a profitable fourth quarter while still closing fiscal 2025 with a sizable net loss and cautious, flat guidance for 2026, a mix that has investors reassessing the stock. See our latest analysis for Quanex Building Products. The upbeat fourth quarter has sparked a sharp near term reset in sentiment, with a 1 month share price return of 25.34 percent and a 7 day gain of 19.28 percent. However,...

ProPetro Holding Corp. recently announced that its PROPWR division signed a contract with a Coterra Energy subsidiary to develop and install distributed microgrids across the New Mexico Permian Basin, lifting committed capacity to over 220 megawatts and prompting higher 2026 capital expenditure guidance of US$250 million to US$275 million. This move accelerates PROPWR’s push toward a one-gigawatt portfolio by 2030 and underscores a shift toward longer-term, power-focused contracts that could...

Earlier this month, Tenaya Therapeutics reported that the FDA lifted the clinical hold on its MyPEAK-1 Phase 1b/2a trial of TN-201 for MYBPC3-associated hypertrophic cardiomyopathy and released encouraging interim Phase 1b/2 data for TN-401 in arrhythmogenic right ventricular cardiomyopathy, while also completing a US$60,000,000 composite units offering. Together, the resumed TN-201 trial and early TN-401 signals highlight Tenaya’s push to use AAV9-based gene therapies to address inherited...

Loews (L) has been getting more investor attention lately, and it is not just sentiment. Recent updates show steady revenue and earnings growth, helped by stronger results at majority owned CNA Financial. See our latest analysis for Loews. Those solid fundamentals seem to be filtering through to sentiment, with Loews’ recent governance tweaks and legal clarity arriving alongside a strong year to date. The share price return is up sharply while multi year total shareholder returns remain very...

If you are wondering whether HCA Healthcare is still worth buying after such a large share price rise, or if the easy money has already been made, this article will walk through whether the current price still stacks up against its fundamentals. Despite a small dip of 0.4% over the last week, HCA shares are up 2.4% over 30 days, 62.8% year to date, 55.3% over 1 year, 107.5% over 3 years, and 207.6% over 5 years, which naturally raises the question of how much upside is left from here. Recent...

Comtech Telecommunications (CMTL) opened fiscal Q1 2026 with revenue of about $111 million and a basic EPS loss of roughly $0.67, putting margins firmly in the red for the quarter. The company has seen quarterly revenue move around the low $100 million range in recent periods, from about $116 million in Q1 2025 to $130 million in Q4 2025 before landing at $111 million this quarter. Basic EPS has stayed negative throughout, ranging from a steep $5.29 loss a year ago to a $0.39 loss last...

If you are wondering whether Par Pacific Holdings is still good value after its big run up, you are not alone, and that is exactly what we are going to unpack here. The stock has cooled off a bit lately, slipping about 7.0% over the last week and 1.1% over the past month, but it is still up 143.4% year to date and 146.8% over the last year. Those moves have come as investors refocus on refining and energy logistics names and reassess how companies like Par Pacific might benefit from changing...

Recently, CSX reported its fastest train velocity since early 2021 and completed major projects such as the Howard Street Tunnel and Blue Ridge subdivision ahead of schedule, enhancing network capacity and resilience. At the same time, the company is tightening its cost base and governance, including shutting an 84-year-old corporate aviation department shortly after appointing new CEO Steve Angel, signaling a sharper focus on efficiency and capital discipline. Now we’ll examine how CSX’s...

Wondering if ImmunityBio at around $2.36 is a speculative trap or a misunderstood bargain? You are not alone, and that is exactly what this breakdown is here to unpack. Despite a bruising longer term record, with the share price down about 17.8% over the last year and 63.4% over three years, the stock has shown signs of life recently, gaining roughly 3.1% in the past week and 14.6% over the last month, while still sitting 8.2% lower year to date. Those moves have come as investors continue...

If you have been wondering whether Capricor Therapeutics is still a smart buy after its big run, you are not alone. This stock has quickly moved from under the radar to front and center on a lot of watchlists. The share price has dipped 3.2% over the last week, but that small pullback sits on top of a 343.3% gain in the last month and a 96.2% return over the past year, with long term holders still up 593.9% over 3 years and 524.0% over 5 years. Behind those moves, investors have been...

If you have ever looked at Main Street Capital and wondered whether the current price really reflects its underlying value, this breakdown is for you. The stock has climbed to around $62.05, delivering about 2.2% over the last week, 4.9% in the last month, 4.7% year to date, and 19.9% over the past year, with multi year gains of 114.1% over 3 years and 190.8% over 5 years reshaping how investors see its potential. Recent headlines have focused on Main Street Capital expanding its portfolio...

Natural Grocers by Vitamin Cottage (NGVC) has wrapped up FY 2025 with fourth quarter revenue of $336.1 million and basic EPS of $0.51, alongside trailing twelve month revenue of about $1.3 billion and EPS of $2.02. Over the last few quarters the company has seen revenue move from $322.7 million in Q4 2024 to $336.1 million in Q4 2025, while quarterly EPS stepped up from $0.40 to roughly the low $0.50s as net income climbed from $9.0 million to $11.8 million. With net margin rising from 2.7%...

Wondering if Arbor Realty Trust at around $8.87 is a beaten down opportunity or a value trap? Let us unpack what the numbers are really saying about the stock. Despite a modest 0.2% gain over the last 7 days, the share price is still down 3.8% over 30 days, 35.6% year to date, and 30.6% over the past year, with only a 6.9% gain over five years. This naturally raises questions about whether the market has become too pessimistic. Recently, the stock has been in the spotlight as investors...

Bio Green Med Solution, Inc.'s (NASDAQ:BGMS) value has fallen 13% in the last week, but insiders who sold US$4.8m worth...

Frequency Electronics (FEIM) just posted Q2 2026 results with revenue of about $17.1 million and basic EPS of roughly $0.18, putting fresh numbers on the board for both the top and bottom line. The company has seen quarterly revenue move from around $15.8 million in Q2 2025 to $17.1 million this quarter, while basic EPS has shifted from approximately $0.28 to $0.18 over the same period, against a trailing-12-month net income backdrop of about $21.0 million. Taken together, the latest print...

Broadcom (AVGO) kicked off FY 2025 with fiscal Q4 revenue of about $18.0 billion and basic EPS of $1.80, capping off a year in which trailing 12 month revenue reached roughly $63.9 billion and EPS climbed to $4.91 as reported earnings jumped 275.4% with net margins advancing to 36.2% from 12% the prior year. The company has seen revenue move from around $51.6 billion on a trailing 12 month basis in late 2024 to $63.9 billion by Q4 2025, while net income over the same window expanded from $6.2...

Wondering if General Mills at around $46.69 is a bargain hiding in plain sight or a classic value trap in the making? This article is designed to help you figure that out with a clear, valuation-first lens. Despite a modest 1.7% gain over the last 7 days and a flat 0.4% over 30 days, the stock is still down a steep 26.5% year to date and 26.8% over the last year, which naturally raises questions about whether sentiment has overshot the fundamentals. Recently, investors have been rethinking...

Wondering if Hims & Hers Health is still a smart buy after its big run, or if the easy money has already been made? You are not alone, and this article is going to unpack exactly what the current price is really baking in. Even after a recent pullback of around 5.1% over the last week and 4.6% over the past month, the stock is still up 47.7% year to date and a massive 450.4% over three years. This tells you the market has already rewritten its expectations in a big way. That surge in...

Wondering if Airbnb at around $128 a share is still a good deal or if the easy money has already been made? This article breaks down what the current price really implies about its future. Despite being down about 2.4% year to date and 2.0% over the last year, the stock has quietly climbed 3.3% in the past week and 5.5% over the last month, hinting that investor sentiment may be starting to turn. That recent strength has come as investors refocus on travel demand normalizing, ongoing product...

If you are wondering whether Toast is actually a bargain at today’s prices or if the easy money has already been made, you are not alone. That is exactly what we are going to unpack. The stock has slipped recently, down about 1.1% over the last week, 8.0% over the last month and 7.5% over the past year, even though it is still up around 88.1% over three years. Much of the recent share price action has been driven by changing market sentiment toward high growth, software enabled payment...

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...

Taking the occasional loss comes part and parcel with investing on the stock market. Unfortunately, shareholders of...

Wondering if Zevra Therapeutics at around $8 a share is a hidden bargain or just another biotech rollercoaster? You are not alone. Let us break down what the current price might really be telling us. The stock is roughly flat over the last year, down 1.8%, but that sits on top of a wild 84.7% gain over three years and a 55.5% drop over five years. This pattern hints at shifting market confidence rather than a simple growth story. Recent attention has centered on Zevra's progress with its...

Ciena (CIEN) just wrapped up FY 2025 with fourth quarter revenue of about $1.4 billion and basic EPS of $0.14, alongside trailing twelve month revenue of roughly $4.8 billion and EPS of $0.87. The company has seen revenue move from $1.1 billion and EPS of $0.26 in Q4 2024 to the latest $1.4 billion and $0.14. On a trailing basis, revenue has stepped up from about $4.0 billion and EPS of $0.58 to $4.8 billion and $0.87, setting the stage for investors to weigh modest net margins against the...